Compare AP & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AP | RFL |
|---|---|---|
| Founded | 1929 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 54.4M |
| IPO Year | N/A | N/A |
| Metric | AP | RFL |
|---|---|---|
| Price | $2.89 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 222.5K | 92.7K |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $426,314,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.20 | ★ 43.96 |
| 52 Week Low | $1.75 | $1.17 |
| 52 Week High | $3.99 | $3.19 |
| Indicator | AP | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 43.20 |
| Support Level | $2.46 | $1.20 |
| Resistance Level | $2.95 | $1.29 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 76.29 | 50.00 |
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.